Table 7.
Non‐HCC group (B) | Non‐HCC group (A) | HCC group (B) | HCC group (A) | P (non‐HCC B vs HCC B) | P (non‐HCC A vs HCC A) | |
---|---|---|---|---|---|---|
1317 G‐A | 4 (20%) | 5 (25%) | 13 (56.5%) | 14 (60.9%) | 0.03 | 0.03 |
1341 T‐C/A/G | 0 (0%) | 0 (0%) | 3/2/1 (26.1%) | 3/3/1 (30.4%) | 0.02 | 0.01 |
1485 C‐T (Xaa38 P‐S) | 2 (10%) | 3 (15%) | 4 (17.4%) | 7 (30.4%) | 0.67 | 0.29 |
1653 C‐T (Xaa94H‐Y) | 5 (25%) | 6 (30%) | 6 (26.1%) | 6 (26.1%) | 1.00 | 1.00 |
1719T‐G (Xaa116L‐V) | 6 (30%) | 5 (25%) | 0 (0%) | 1 (4.3%) | <0.01 | 0.08 |
1753 T‐C/A/G (Xaa127I‐T/N/S) | 5/1/1 (35%) | 5/1/1 (35%) | 6/4/0 (43.5%) | 8/1/2 (47.8%) | 0.76 | 0.54 |
1762 A‐T (Xaa130K‐M) | 12 (60%) | 12 (60%) | 20 (87.0%) | 20 (87.0%) | 0.08 | 0.08 |
1764 G‐A (X131V‐I) | 11 (55%) | 15 (75%) | 21 (91.3%) | 21 (91.3%) | 0.01 | 0.22 |
1896 G‐A (preC28 W‐stop) | 4 (20%) | 7 (35%) | 9 (39.1%) | 9 (39.1%) | 0.20 | 1.00 |
1938 T‐C (core13 V‐A) | 0 (0%) | 0 (0%) | 2 (8.7%) | 4 (17.4%) | 0.49 | 0.11 |
2189 A‐C/T (core97 I‐L/F) | 3/0 (15%) | 5/1 (30%) | 5/0 (21.7%) | 4/1 (21.7%) | 0.70 | 0.73 |
2288 C‐A/G (core130 P‐T/A) | 2/0 (10%) | 4/1 (25%) | 8/1 (39.1%) | 6/2 (34.8%) | 0.04 | 0.53 |
3026 C‐A/T (pre‐S160 A‐V/E) | 0 (0%) | 0 (0%) | 4/1 (21.7%) | 5/1 (26.1%) | 0.05 | 0.02 |
53 T‐C (pre‐S222 F‐L) | 2 (10%) | 4 (20%) | 2 (8.7%) | 5 (21.7%) | 1.00 | 1.00 |
Pre‐S2 deletion | 0 (0%) | 0 (0%) | 8 (34.8%) | 7 (30.4%) | <0.01 | 0.01 |
162 A‐G (S3 N‐S) | 8 (40%) | 8 (40%) | 12 (52.2%) | 12 (52.2%) | 0.54 | 0.54 |
357 T‐C (S68 I‐T) | 0 (0%) | 1 (5%) | 6 (26.1%) | 5 (21.7%) | 0.02 | 0.19 |
531 T‐C/G (S126 I‐T/S) | 3/2 (25%) | 3/3 (30%) | 7/2 (39.1%) | 7/2 (39.1%) | 0.35 | 0.75 |
706 A‐C (S184 V‐A) | 11 (55%) | 11 (55%) | 14 (60.9%) | 13 (56.5%) | 0.76 | 1.00 |
1386 G‐C/A (X5 V‐M/L) | 4/1 (25%) | 3/1 (20%) | 4/4 (34.8%) | 3/6 (39.1%) | 0.33 | 0.20 |
1320 A‐C (Pol743 K‐N) | 1 (5%) | 1 (5%) | 7 (30.4%) | 7 (30.4%) | 0.05 | 0.05 |
P‐values for comparisons between the indicated groups are shown. P < 0.05 is indicated by italic type. Non‐hepatocellular carcinoma (HCC) group (B): at the beginning of follow‐up in patients who did not develop HCC. Non‐HCC group (A): at the end of follow‐up in patients who did not develop HCC. HCC group (B): at the beginning of follow‐up in patients who developed HCC. HCC group (A): at the diagnosis of HCC in patients who developed HCC.